During the period of event accrual , vorapaxar was associated with a 26 % reduction in the composite of cardiovascular death , myocardial infarction , or stroke when used with clopidogrel ( hazard ratio [ HR ] 0.74 ; 95 % CI 0.60-0 .91 ) and a 24 % reduction when used without clopidogrel ( HR 0.76 ; 95 % CI 0.56-1 .02 ) ( interaction ; P = .89 ) .